RGFP966, a highly selective HDAC3 inhibitor, has demonstrated neuroinhibitory and neuroprotective impacts in several central nervous system diseases, encompassing neurodegenerative diseases [29], cerebral ischemia [30] and spinal cord injury [31]. Here, HDAC3 is linked to neurodegenerative disease.